Twenty-four mobilized peripheral blood products from healthy donors for allogeneic transplantation were positively selected for CD34
The development of HLA-mismatched or haploidentical donor stem cell transplantation requires a high degree of T cell depletion (TCD) while preserving an adequate number of CD34
+ cells in the graft in order effectively to prevent acute graft-versus-host disease (aGVHD) and ensure engraftment. [1] [2] [3] Several reasons make CD34 positive cell selection methods (positive selection, + selection) particularly attractive to deplete T cells especially in peripheral blood progenitor cell (PBPC) grafts: they can be applied to the large numbers of cells present in PB, they are able to preserve adequate numbers of progenitors after selection, thus maintaining the potential benefits of a PBPC transplant in this setting and they passively deplete the elevated numbers of T cells present in the PB grafts.
Several methods are available for positive selection. [4] [5] [6] [7] The immunomagnetic technique, which is now exploited by the Isolex 300i cell selection technology (Nexell Therapeutics, Irvine, CA, USA), involves specific binding of target cells by a mouse anti-CD34 MoAb, 9C5. The target cells-9C5 complexes are then captured by sheep antimouse IgG-coated paramagnetic beads (IB) (SAM-M450; Dynabeads, Dynal, Oslo, Norway) and in a final step target cells are released from the 9C5-IB complexes by a peptide that binds competitively to the 9C5 MoAb. 8 This method achieves between 3 and 4 logs of TCD, 9 thus resulting in T cell doses in the allograft lower than those suggested to trigger aGVHD in the T cell-depleted BM of the HLAmatched setting. [10] [11] [12] [13] However, in recipients of HLAmismatched or haploidentical donor grafts, a higher TCD of the graft may be required to avoid aGVHD. 2, 3 Methods that allow additional T cell removal from the purified CD34 + cell product combining both CD34 positive and T negative cell selections (positive/negative selection, +/− selection) are of clinical relevance. In this sense, CD34 + cell-enriched components obtained with the Isolex 300i device leave cell surface antigens intact and free of surfacebound reagent and allow additional rounds of negative cell selection.
Here, we analyse the effectiveness of combined CD34 positive and T cell negative immunomagnetic selection strategies (+/− selection) for PBPC in the allogeneic setting; a sequential, 'two-step' +/− selection (Isolex 300i for CD34 positive selection and the Max-Sep device for T cell negative selection) has been investigated and a new strategy of Bone Marrow Transplantation simultaneous, 'one-step' +/− selection by the use of the Isolex 300i device (for both, CD34 positive and T cell negative selection) has been analyzed. Potential improvements achieved with the newly developed software for the Isolex 300i (version 2) have been compared with the previous system (version 1).
Materials and methods

Donors
Twenty-four fresh PBPC products from 14 healthy donors collected after mobilization of hematopoietic stem cells with glycosylated rhG-CSF were processed. In 11 cases the donor was an HLA-mismatched sibling and in three cases an HLA-identical sibling.
Leukaphereses (LK) obtained with a COBE Spectra (COBE, Lakewood, CO, USA) or a CS3000 (Fenwal, Baxter Healthcare, Deerfield, IL, USA) devices were started when the WBC count in PB exceeded 1.0 × 10 9 /l and the CD34 + cell count 20 × 10 3 cells/ml. All donors had given written informed consent and the study had been previously approved by the local ethics and research committees. Max-Sep for negative selection: A negative selection step was performed afterwards in an attempt to optimize the TCD to that achieved with the positive selection process. The CD34
+ cell-enriched component obtained with the Isolex 300i was transferred to a Lifecell bag (Baxter). Without further manipulation, the cell suspension was incubated with CD4 and CD8 MoAbs previously bound to IB. CD4-IB and CD8-IB complexes were added to the cell suspension to give a final concentration of 10 × 10 6 of CD4-IB and CD8-IB/ml, which had been found optimal in preclinical assays (data not shown), and incubated for 30 min, at 4°C, on end-over-end rotation at 4 r.p.m. Rosetted target cells were then captured by exposure to the magnet of the MaxSep device (Baxter Healthcare) following the recommendations of the manufacturer.
Simultaneous 'one-step' +/− selection with Isolex 300i
Software version 1: A combined approach of simultaneous +/− cell selection can be easily adapted to the Isolex 300i version 1 system following the manufacturer's indications. In some procedures (n = 4) a +/− selection was performed as follows: during the procedure of positive selection step and following the transfer of the peptide release agent to the primary chamber, CD4-IB and CD8-IB complexes were added to it and gently mixed. These complexes would bind to the residual contaminating T cells and retain them in the magnetic field (negative selection step); CD34 + cells will then be released from the 9C5 MoAb-IB complexes into the fluid phase. Concentration of IB-MoAb complexes in the primary chamber was approximately 10 × 10 6 /ml. The rest of the process was allowed to continue with the automated machine.
Software version 2:
The up-grade software of the Isolex 300i machine (version 2.0) has been adapted to perform all steps of combined +/− cell selection automatically. The CD4 and CD8 MoAb (0.5 mg of each) and the IB (4 × 10 9 ) reagents were introduced into the primary chamber of the machine at different times when indicated by the device. The additional negative selection step was done as follows: during the last wash of the CD34 + cells-9C5 MoAb-IB complexes from the positive selection step, an additional incubation with CD4 and CD8 MoAb would bind to the residual contaminating T cells (negative selection step). After a mixing phase, the procedure continues until the transfer of the release peptide to the chamber takes place; at that time, additional IB are added. CD34
+ cells are released from the 9C5 MoAb-IB complexes into the fluid phase, the additional IB bind the target cells of the negative selection step and retain them in the magnetic field.
Cell viability was evaluated by Trypan Blue dye exclusion in the LK products and in the final fractions. All cell counts were performed using a Coulter JT3 counter (Coulter Electronic, Hialeah, FL, USA).
Cytometry analyses
Samples from LK products before separation, CD34
+ cellenriched, CD34
+ cell-enriched T cell-depleted and CD34
+ cell-depleted components were obtained for CD34 + cell enumeration as previously reported in detail. 9 Briefly, cells were incubated with human AB serum and anti-CD34-PE MoAb (8G12, HPCA-2; Becton Dickinson, San Jose, CA, USA) for 15 min at RT in the dark. After washing twice, the samples were incubated for 10 min at RT with ammonium chloride (Ortho Lysing Reagent; Ortho, Raritan, NJ, USA) for erythrocyte lysis. Cells were then incubated with 7-aminoactinomycin-D (7-AAD; Molecular Probes, Eugene, OR, USA) for 5 min at RT. 
Clonogenic assays
Clonogenic assays were performed in PBPC before separation, CD34
+ cell-enriched, CD34 + cell-enriched T celldepleted and CD34
+ cell-depleted components. A commercially prepared methylcellulose-based medium (Methocult GF 4434; Stem Cell Technologies, Vancouver, Canada) was used as previously described.
14 Assays were run in triplicate. Cultures were incubated at 37°C and 5% CO 2 . Colonies were enumerated using an inverted microscope after 14 days of culture.
Statistical analyses
Data are shown as medians and ranges unless otherwise indicated. Continuous variables were compared using the Mann-Whitney U test or Wilcoxon rank test. A P value lower than 0.05 was considered significant. Statistical analyses were performed using the SPSS 7.5 software (SPSS, Chicago, IL, USA).
Results
Processing
All the selection procedures on a clinical scale were done from a single LK. The median number of LK per donor was one (range 1-3). Results are shown in Tables 1 and 2 . + and CD8 + cell depletions in the positive selection (first step) were 3.7 log (3-3.8) and 3.7 log (3-3.8), respectively. Additional CD4
+ and CD8 + cell depletions performed with the MaxSep device in the CD34 + cell-enriched component gave a final depletion of 4.8 log (4.5-5.8) and 4.3 log (3.9-5.6), respectively. The median increases of TCD (log) (= TCD double selection (log) − TCD first selection step (log)) in the negative selection step for CD4 and CD8 were 1.4 (1.1-2.0) and 0.9 (0.5-1.8). CD34
+ cell yield during the second step of negative selection was 93% (86-106). cell depletions in the first step of the procedure were 4.6 log (3.4-4.8) and 4.5 log (3.5-4.8), respectively, higher than those achieved with the version 1 (P = 0.07). Additional CD4 + and CD8 + cell depletions performed with the MaxSep device in the CD34 + cell-enriched component gave final depletions of 5.1 log (4.7-5.9) and 5.1 log (4.1-5.3), respectively. The median increases of TCD (log) in the negative selection step for CD4 and CD8 were 0.7 (0-1.4) and 0.6 (0.2-0.8). CD34
Isolex 300i version 2 (n = 5): NC and percentage of CD34
+ cell yield during the second step of negative selection was 99% (82-112).
Simultaneous 'one-step' +/− selection Isolex 300i version 1 (n = 4): NC load and percentage of starting CD34
+ cells in the Isolex 300i version 1 were 4.7 × 10 10 (2.9-5.5) and 1% (0.6-1.1), respectively. Logs of CD4
+ and CD8 + cell depletions were 4.2 (4-4.5) and 3.8 (3.8-4.1), and CD34
+ cell purity and yield in the double selected component were 76% and 39%, respectively.
Isolex 300i version 2 (n = 10): NC load and percentage of starting CD34
+ cells in the Isolex 300i version 2 were 3.2 × 10 10 (1.8-6.5) and 0.97% (0.7-1.7), respectively.
Logs of CD4
+ and CD8 + cell depletions were 5 (4.5-5.6) and 4.9 (4.2-5.5), respectively, higher than those obtained with version 1 (P Ͻ 0.005). CD34
+ cell purity and yield in the final, double-selected component were 97% and 57%, respectively, also higher than with version 1 (P Ͻ 0.005 and P = 0.07).
Clonogenic assays
Recoveries of CFU-GM in the CD34
+ cell-enriched components after + and +/− selection steps were 35% (24-55) and 22% , respectively (n = 8). Recovery of CFU-GM in the double-selected product was 18% (3-70) (n = 14) for simultaneous +/− selection procedures and in the CD34 + cell-depleted component was 6% (1-58) (n = 22) for all procedures. Clonogenic efficiencies (for all CFU-GM, BFU-E and CFU-Mix) per CD34 + cell in the initial, CD34
+ cell-enriched, CD34 + cell-enriched/T cell-depleted and CD34
+ cell-depleted components were 27% (7-124), 10% (6.5-20), 14% (6.5-27) and 27% (6-119), respectively. Cell viability as determined by Trypan blue dye exclusion was 99% (93-100) in the initial material and 96% (88-99) in the final double-selected product.
Discussion
In the present study we analyzed the effectiveness of combined CD34 positive and T cell negative selection on PBPC for allogeneic transplantation using different immunomagnetic strategies.
The results obtained with a simultaneous +/− cell selection with the Isolex 300i device version 2 with a median 5 log TCD, nearly 60% CD34 + cell yield and more than 90% of CD34 + cell purity, compare favorably with those obtained with the previous software version of this machine. Moreover, when the results obtained with the positive selection step were analyzed, a higher CD34 + cell 
CD8
− cell selection was performed with the Isolex 300i device (software version 1 or 2). TCD (log 10 ) = CD3 + cell depletion. ⌬ TCD (log 10 ) = TCD (double selection) (log 10 ) − TCD (first selection step) (log 10 ). a P Ͻ 0.05; b P = 0.3; c P = 0.07; d P Ͻ 0.005; e P = 0.07. NA = not applicable.
Table 2
Percentage of T lymphoid cell subsets in the different cellular components of allogeneic PBPC after a double CD34 positive/CD4 and CD8 negative selection Results are shown as median and range. Sequential (two-step) CD34
− selections were done with the Isolex 300i (version 1 or 2) (positive selection step) followed by negative selection with the MaxSep device. Simultaneous (one-step) selections were performed with the Isolex 300i (software version 1 or 2). NA = not applicable.
purity and yield and a higher rate of TCD, in the order of 4.5 log, were obtained with version 2 with respect to version 1. On the other hand, as the final CD34
+ cell component obtained with this technique is free of the residual reagents used during the procedure, an additional purging effect may be achieved by combining it with a second negative immunomagnetic step if the T cell content of the graft is higher than is desirable. In this sense, our processing protocol of negative selection with the Max-Sep device may increase the TCD by about 0.5-1 log compared to that obtained with the positive selection procedure alone with minimal additional CD34 + cell losses. Different strategies have been used to deplete T cells from allo-PBPC grafts. Dreger et al 15 used a negative cell selection approach with Campath-1 MoAb and complement and obtained about 2 log TCD and a 56% CD34 + cell recovery. Rambaldi et al 16 described a two-step negative selection by incubation with CD2 and CD7 magnetic microbeads and separation with magnetic field depletion columns after debulking the graft of mature cells by an immune rosetting technique. They achieved 3 log TCD with a CD34 + cell yield of 70%. Nevertheless, these approaches result in T cell numbers in the graft that may still trigger GVHD, particularly in transplants across HLA barriers. 2, 3 A new approach to reduce the high numbers of T cells present in the allo-PBPC grafts is CD34 + cell selection. Various methods have been developed for CD34
+ cell purification in the clinical setting. The biotin-avidin-mediated CD34 + cell selection method (Ceprate system) achieves about 3 log TCD and 60-70% CD34 + cell purity and yield. 7 In order to increase the TCD with this technique, some authors have applied a T cell-depletion step after selection of CD34 + cells. For instance, Bertolini et al 17 have tested a step of negative selection with anti-CD3 MoAb and magnetic colloidal particles by using the StemSep device to deplete T cells from the CD34 + cell-enriched component obtained with the Ceprate system in laboratory-scale samples. They reported a 4.5 log TCD with about 50% of CD34 + cell recovery. Similar results were obtained by Martin-Hernandez et al 18 with an anti-CD2 biotinylated MoAb and immunoadsorption depletion columns after positive selection using the same system. However, the Ceprate system is no longer available for this purpose. Schumm et al 19 
obtained a CD34
+ cell yield of 60-70% and a purity greater than 90% with a residual CD3 + cell content in the enriched component below 1% by using a magnetic field separation device (Clinimacs system). Similar results were obtained by McNiece et al, 20 who reported 4 to 5 log TCD with the same system. It should be noted that magnetic particles remain bound to the CD34 + cells in the enriched component obtained with this system, thus raising doubts about the effectiveness of additional magnetic purging steps if the T cell content of the purified component is higher than is desirable.
The double-selected CD34 + /T cell-depleted component showed normal in vitro proliferation. Recovery of CFU-GM and clonogeneic efficiency after the second step of negative selection was similar to that obtained after positive selection alone indicating minimal clonogeneic cell losses after the additional negative selection step.
In conclusion, our data indicate that the simultaneous, one-step +/− selection method with the Isolex 300i version 2 device is an effective technique able to obtain high degrees of TCD with a high CD34
+ cell purity and an acceptable yield. This would result in a final graft with very low numbers of T cells and high numbers of CD34 + cells that might avoid severe aGVHD while preserving rapid engraftment in the HLA-mismatched allogeneic setting.
